Indications
LysaKare is indicated for reduction of renal radiation exposure during Peptide-Receptor Radionuclide Therapy (PRRT) with lutetium (177Lu) oxodotreotide in adults.
Composition
- Active substance
- L-arginine hydrochloride, L-lysine hydrochloride
- International name (INN)
- arginine;lysine
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- LysaKare
- Active substance
- L-arginine hydrochloride, L-lysine hydrochloride
- ATC code
- V03AF11
- Group
- Various
- Therapeutic area
- Radiation Injuries
- Marketing authorisation holder
- Advanced Accelerator Applications